JP2015520175A - インターロイキン−４アンタゴニストを伴うワクチン接種 - Google Patents

インターロイキン−４アンタゴニストを伴うワクチン接種 Download PDF

Info

Publication number
JP2015520175A
JP2015520175A JP2015515352A JP2015515352A JP2015520175A JP 2015520175 A JP2015520175 A JP 2015520175A JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015515352 A JP2015515352 A JP 2015515352A JP 2015520175 A JP2015520175 A JP 2015520175A
Authority
JP
Japan
Prior art keywords
antigen
antagonist
virus
interleukin
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015515352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520175A5 (enExample
Inventor
ロナルド・ジェイムズ・ジャクソン
チャラニ・ラナシンヘ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Australian National University
Original Assignee
Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902345A external-priority patent/AU2012902345A0/en
Application filed by Australian National University filed Critical Australian National University
Publication of JP2015520175A publication Critical patent/JP2015520175A/ja
Publication of JP2015520175A5 publication Critical patent/JP2015520175A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2015515352A 2012-06-05 2013-06-05 インターロイキン−４アンタゴニストを伴うワクチン接種 Pending JP2015520175A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902345 2012-06-05
AU2012902345A AU2012902345A0 (en) 2012-06-05 Vaccination with Interleukin-4 Antagonists
PCT/AU2013/000589 WO2013181696A1 (en) 2012-06-05 2013-06-05 Vaccination with interleukin-4 antagonists

Publications (2)

Publication Number Publication Date
JP2015520175A true JP2015520175A (ja) 2015-07-16
JP2015520175A5 JP2015520175A5 (enExample) 2016-07-21

Family

ID=49711200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515352A Pending JP2015520175A (ja) 2012-06-05 2013-06-05 インターロイキン−４アンタゴニストを伴うワクチン接種

Country Status (15)

Country Link
US (1) US20150150963A1 (enExample)
EP (2) EP3530283A1 (enExample)
JP (1) JP2015520175A (enExample)
KR (1) KR20150021088A (enExample)
CN (1) CN104717971A (enExample)
AU (1) AU2013271338B2 (enExample)
BR (1) BR112014030436A2 (enExample)
CA (1) CA2875683A1 (enExample)
HK (1) HK1203358A1 (enExample)
IL (1) IL236092A0 (enExample)
IN (1) IN2014DN10408A (enExample)
NZ (1) NZ702721A (enExample)
SG (1) SG11201408101TA (enExample)
WO (1) WO2013181696A1 (enExample)
ZA (1) ZA201409076B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515260A (ja) * 2020-04-17 2023-04-12 シャンハイマブギークバイオテック．カンパニー，リミティド 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014202A1 (en) * 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3282188B2 (ja) 1991-06-27 2002-05-13 日本電気株式会社 半導体メモリ装置
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP1715046B1 (en) 1993-03-31 2009-04-29 Zeon Corporation New polypeptide, DNA encoding the polypeptide, recombinant vector bearing the DNA and recombinant virus utilizing the recombinant vector as well as use thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ES2192573T3 (es) 1994-01-21 2003-10-16 Powderject Vaccines Inc Instrumento de deposito de genes mediante arrastre gaseoso.
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1998000524A1 (fr) 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1042494A1 (en) 1997-12-23 2000-10-11 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
US7250299B1 (en) 1999-04-29 2007-07-31 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7125705B2 (en) 2000-04-28 2006-10-24 Genzyme Corporation Polynucleotides for use in recombinant adeno-associated virus virion production
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
WO2004028563A1 (en) 2002-09-27 2004-04-08 Genexine Inc. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8048404B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
RU2465326C2 (ru) 2005-04-24 2012-10-27 Санофи Пастер Байолоджикс Ко Рекомбинантные флавивирусные вакцины
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
CA2635996A1 (en) * 2006-01-11 2007-07-19 Aerovance, Inc. Methods and compositions for treating asthma in human and non human primates
AR066240A1 (es) * 2007-04-23 2009-08-05 Wyeth Corp Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13
EP2414520A2 (en) * 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Methods of modulating an immune response to a viral infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VACCINE, vol. Vol.20, No.5-6, JPN6017025861, 2001, pages 688 - 705, ISSN: 0003699863 *
別冊実験医学 ザ・プロトコ ールシリーズ 遺伝子導入＆発現解析実験法, JPN6017047358, 1997, pages 43 - 51, ISSN: 0003699864 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023515260A (ja) * 2020-04-17 2023-04-12 シャンハイマブギークバイオテック．カンパニー，リミティド 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用
JP7454882B2 (ja) 2020-04-17 2024-03-25 シャンハイマブギークバイオテック．カンパニー，リミティド 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用
US11939387B2 (en) 2020-04-17 2024-03-26 Shanghai Mabgeek Biotech. Co., Ltd Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof

Also Published As

Publication number Publication date
EP3530283A1 (en) 2019-08-28
IL236092A0 (en) 2015-01-29
KR20150021088A (ko) 2015-02-27
NZ702721A (en) 2016-11-25
CA2875683A1 (en) 2013-12-12
WO2013181696A1 (en) 2013-12-12
BR112014030436A2 (pt) 2017-09-26
ZA201409076B (en) 2017-06-28
AU2013271338B2 (en) 2018-05-24
IN2014DN10408A (enExample) 2015-08-14
EP2854837A4 (en) 2016-06-29
EP2854837A1 (en) 2015-04-08
CN104717971A (zh) 2015-06-17
AU2013271338A1 (en) 2015-01-15
SG11201408101TA (en) 2015-01-29
HK1203358A1 (en) 2015-10-30
US20150150963A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
AU2018267669B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CN102782136A (zh) 表达hiv抗原和gm-csf的载体和用于产生免疫应答的相关方法
Jackson et al. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy
JP2006523224A (ja) 免疫原性組成物および方法
JP2015116196A (ja) レンチウイルスベースの免疫原性ベクター
US10729762B2 (en) HIV immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto
RU2302461C2 (ru) Химерный ген cr3 и кодируемый им химерный белок cr3 (варианты), индуцирующий иммунный ответ против вич-1
Buffa et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo
US20170106081A1 (en) Cellular vaccine and method of inducing an immune response in a subject
JP2015520175A (ja) インターロイキン−４アンタゴニストを伴うワクチン接種
KR20190123257A (ko) Sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
JPWO2007102326A1 (ja) アデノウイルス５型／３５型ベクターとワクシニアウイルスｍｖａベクターとの併用による強力な免疫誘導
US20130337009A1 (en) Chimeric dna vaccine compositions and methods of use
JP2022536850A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
JP2022537324A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ
US20170107260A1 (en) Mosaic hiv-1 sequences and uses thereof
JP5635950B2 (ja) 免疫原性組成物および方法
Jones et al. Optimized Mucosal MVA Prime/Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen
KR20190121289A (ko) Cd40 및 sting 경로를 활성화하는 유전자 보조제의 발현을 위한 바이러스 벡터 작제물
Biragyn et al. DNA vaccines encoding HIV-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses
JP2024509976A (ja) 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
Gardner Genetic Immunization for Lentiviral Immunodeficiency Virus Infection and Disease.
OA18541A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ767061B2 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
NZ767061A (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20150128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171212